The clinical-stage biotech company, Cugene, is dedicated to developing next-generation precision immunology and oncology medicines that harness specific immune cells to treat autoimmune disease and cancer. Their innovative bioengineering approach allows for the creation of novel therapeutics that provide specificity and efficacy while limiting unwanted side effects on neighboring healthy tissues. By harnessing the power of the human immune system, Cugene's medicines aim to fight disease in a more targeted and effective way.